Latest News and Press Releases
Want to stay updated on the latest news?
-
TEL-AVIV, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage...
-
The randomized, double-blind, placebo-controlled, parallel group Phase III study with RHB-102 (the GUARD study) will enroll 320 acute gastroenteritis patients in the U.S. Acute...
-
In order to enhance statistical powering and expedite recruitment, RedHill has increased the number of subjects and clinical sites, respectively, in the ongoing RHB-105 Phase III ERADICATE Hp...
-
Potentially expanding its gastrointestinal-focused pipeline, RedHill has secured an option to acquire RP101 from Dresden-based RESprotect GmbH, a spin-off from the Fraunhofer-Society RP101...
-
Highlights include: A strong cash position of approximately $34 million at the end of the second quarter of 2014, following the acquisition of rights to MESUPRON®, a Phase II drug...
-
TEL-AVIV, Israel, July 16, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage...
-
RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...
-
The Company, primarily focused on gastrointestinal and inflammatory-related diseases and conditions, including cancer, is currently assessing the possibility of a Phase II proof of concept study...
-
TEL-AVIV, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
-
TEL-AVIV, Israel, June 11, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...